AiM’s neurosurgical surgical robot is MRI-compatible, which facilitates intelligent intraoperative surgical planning and guidance through real-time soft tissue imaging. Image Credit: solar22 / Shutterstock.

AiM Medical Robotics has partnered with Harvard Medical School’s affiliate Brigham and Women’s Hospital (BWH) to conduct a study validating its robot for deep brain stimulation (DBS) in patients with Parkinson’s disease.

The study will take place in BWH’s advanced multimodality image-guided operating (AMIGO) suite and will be supported by the surgical navigation and robotics lab at Harvard.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As per AiM, DBS leads can miss the intended target area owing to brain-shifting due to surgery to create access holes in the skull, compared to preoperative imaging. This brain shift can cause inconsistent and suboptimal outcomes in many procedures, as the target moves relative to the skull during surgery. Approximately a third of DBS lead placements require revision or removal surgeries due to lead missing intended targets.

AiM plans to use its stereotactic neurosurgery robot to accurately deliver DBS leads with real-time MRI guidance in patients with Parkinson’s to avoid brain-shifting issues. The company has reported a successful cadaver trial at the BWH’s PracticePoint facility. This trial demonstrated the precise delivery of bilateral DBS leads using real-time MRI guidance. The procedure was completed entirely within the MRI suite.

AiM’s neurosurgical surgical robot is MRI-compatible which facilitates intelligent intraoperative surgical planning and guidance through real-time soft tissue imaging. The company partnered with Canada-based Synaptive Medical to integrate the latter’s Modus Nav neuro-navigation software platform with AiM’s neurosurgery robot, to allow for enhanced visualisation, navigation, and control.

Robotic surgical systems have grown in popularity in recent years. According to GlobalData analysis, the surgical robotics market was worth approximately $7.2bn in 2023. It is expected to have a strong compound annual growth rate (CAGR) of 8.5% to be worth $10.3bn by 2030.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

There have been multiple recent advancements in the field of surgical robotics such as the use of 5G to allow for remote robotic surgery. In December 2023, Microbot Medical partnered with Corewell Health to develop telerobotics between remote centres by utilising the Liberty endovascular robotic surgical system. The telerobotics functionality will allow for the surgical procedure to take place without the presence of the surgeon at the concerned site.

Companies including EndoQuest Robotics and Omnivision are also working to integrate imaging into surgical robots. In January, the companies partnered to integrate Omnivision’s OCHFA CameraCubeChip image sensor into EndoQuest’s flexible robotic system.